Adipose-vascular targeting
Lab research
Experimental obesity research; the exact compound and species matter.2
Metabolic
Adipotide
Adipose-vascular targeting peptidomimetic (prohibitin-TP01)
Investigational; no FDA-approved adipotide formulation.
What does it do?
Molecular information
4Amino-acid sequence
An exact sequence has not been verified for this formulation.
LengthNot independently verified
Molecular weight · DaNot independently verified for the exact supplied form
Molecular formulaNot independently verified for the exact supplied form4
Salt, hydration, glycosylation and blend composition may change the supplied material; no unsupported formula or mass is assigned.
Pharmacokinetics
Reported half-lifeNo verified human estimate4
No numerical curve is shown without an exact compound, formulation and human-route match.
No numerical estimate was found in the checked data or Pep-Pedia profile. A curve would require an unsupported assumption.
What to expect
Study outcomes
Newer research uses a different analogue
The 2025 mixed-chirality study evaluated a modified prohibitin-targeting compound in obese mice. It does not verify adipotide efficacy, preparation or dosing in people.2
Primate weight loss with renal effects
Obese monkeys lost weight and white adipose tissue; renal proximal-tubule function changed. The study does not establish human safety.3
Reported timelines
Reference & communityWeeks 1–2 / 2–4
Reference sequence: abdominal circumference then fat/weight changes; possible rebound after stopping. Not validated human timelines.13
These are reported timelines, not a prediction of your response.
Doses & schedules
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| SubQSubQ (escalating tiers) | 0.10–0.75 mg/kg | Once daily | Dose‑finding (research)Reference report | 28 days | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Injectable
- Use period
- 28 days
- Break
- ≥4 weeks
Reported timing
Consistent daily timing; monitor hydration
Animal and cell protocols 2
Laboratory exposures cannot establish a human dose.
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| SubQSubcutaneous | 0.43 mg/kg | Daily | Fixed-dose primate experimentObese rhesus monkeysAnimals | 28 days | 3 |
Population Obese rhesus monkeys Context Animal experiment only; do not convert this to human dosing. | |||||
| SubQ | 0.43 mg/kg | Once daily | Primate research replicationReference report | 28 days | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
No protocols match these filters.
Side effects & safety
Kidney toxicity signal
Reversible renal proximal-tubule changes occurred in primate experiments.
3Kidneys
Primate proximal-tubule injury, creatinine/electrolyte changes; reduced urine or sustained abnormalities need assessment.
Other symptoms
Severe injection/systemic reactions or unexpected toxicity.
Pregnancy
Pregnancy/lactation safety unstudied.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
9 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
Semaglutide
Caution reportedGI/dehydration and renal concerns.13
Reference report · Pep-Pedia label: Monitor CombinationTirzepatide
Caution reportedVolume/electrolyte and renal concerns.13
Reference report · Pep-Pedia label: Monitor CombinationCJC-1295 / Ipamorelin
Caution reportedMetabolic/body-composition confounding.13
Reference report · Pep-Pedia label: Use CautionNephrotoxic drugs: NSAIDs / aminoglycosides
Avoidance reportedPotential additional kidney injury.13
Reference report · Evidence context: Avoid claimCagrilintide
Unverified pairingNo combination data.13
Reference report · Evidence context: UnknownAOD-9604
Unverified pairingNo combination data.13
Reference report · Evidence context: UnknownBPC-157
Unverified pairingDifferent targets do not establish safety.13
Reference report · Pep-Pedia label: CompatibleMelanotan II
Unverified pairingTheoretical vascular/blood-pressure concerns.13
Reference report · Pep-Pedia label: Requires TimingOther medicines and research compounds
Not establishedNo clinical interaction study for the exact proposed combination was verified; absence of evidence does not establish compatibility.4
Research contextNo matching interactions. Try another name or filter.
Reconstitution
No universal bacteriostatic-water volume or validated preparation method is established for this entry.4
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Injectable
Pep-Pedia describes preparation for this route; product-specific stability has not been independently verified.
- Solvents mentioned
- Bacteriostatic water
- Reported parameters
- Source temperature: 2–8°C.
The source describes gentle mixing and avoiding vigorous shaking.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearanceIntact Lyophilized CakeReported appearanceClear SolutionReported variationMinor ClumpingReported concernCollapsed/Moist CakeReported concernCloudiness/Precipitate
13Available forms
No verified packaging examples included.
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
Refrigerated lifetime not established
The checked sources do not establish how long this research preparation remains stable and sterile after mixing.13
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Evidence limits
View findings →Human efficacy and a safe dose are unverified.2
3 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Research findings
PreclinicalCompound identity & other names
An experimental compound designed to damage blood vessels supporting white adipose tissue. Animal weight-loss findings must be considered alongside kidney toxicity and the absence of verified human efficacy.
Other names: Adipotide (Prohibitin‑TP01)
Investigational; no FDA-approved adipotide formulation.
Adipose-vascular targeting peptidomimetic (prohibitin-TP01)4
How it may work
A vascular-targeting sequence delivers a mitochondrial-disrupting motif, killing targeted endothelial cells.13
Newer research uses a different analogue
The 2025 mixed-chirality study evaluated a modified prohibitin-targeting compound in obese mice. It does not verify adipotide efficacy, preparation or dosing in people.
2Primate weight loss with renal effects
Obese monkeys lost weight and white adipose tissue; renal proximal-tubule function changed. The study does not establish human safety.
3Research areas and evidence gaps
Adipose-vascular targeting. Experimental obesity research; the exact compound and species matter.2
- Human efficacy and a safe dose are unverified.
- Research-market product identity, purity and formulation cannot be established from a publication.
Additional uses listed by Pep-Pedia
Weight / metabolism. Primate fat-mass reduction and improved insulin responses; not human efficacy.13
Appetite. Peripheral mechanism rather than established appetite suppression.13
Community reports Unvalidated
Pep-Pedia describes community interest and schedules; these are secondary reports, not measured clinical outcomes.4
No representative survey, independently verified products, or controlled outcomes.
Search coverage and review status
The targeted check identified relevant additional literature or current regulatory information; checked findings are separated from retained bibliography-only references.
- Checked
- 2026-10-12
- Search
- adipotide prohibitin TP01 2025 2026 study site:pubmed.ncbi.nlm.nih.gov
- Catalog
- Pep-Pedia ↗ · 10 listed references retained
- Targeted search, not an exhaustive systematic review.
- Bibliography-only entries are retained for traceability and are not treated as verified findings.
AI-prepared summaries. Independent medical editorial review is pending.
Community poll 10 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Experience
Number of responses to this question: not disclosed.
Duration of use
Number of responses to this question: not disclosed.
Age range
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Primary goal
Number of responses to this question: not disclosed.
Effectiveness
Number of responses to this question: not disclosed.
Side effects
Number of responses to this question: not disclosed.
Dosage frequency
Number of responses to this question: not disclosed.
Would recommend
Number of responses to this question: not disclosed.
How discovered
Number of responses to this question: not disclosed.
Source & limitations
The source displays “95 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
References
Original sources and review status. Open a reference to read its summary.
1Obese rhesus macaques – fixed-dose efficacy & safety; dose-finding (2011)Abstract checked
AI-PREPARED SUMMARY
Primate experiment found weight and fat loss with reversible renal proximal-tubule changes; no human efficacy conclusion.
Pep-Pedia bibliography · Checked 2026-10-12
2Mixed-Chirality Prohibitin Peptide: D-(RLARLAR)2 Enhances Stability and In Vivo Effects on ObesityAbstract checked
AI-PREPARED SUMMARY
2025 mouse study concerns a modified prohibitin-targeting analogue, not a human trial of adipotide.
Newer research uses a different analogue
The 2025 mixed-chirality study evaluated a modified prohibitin-targeting compound in obese mice. It does not verify adipotide efficacy, preparation or dosing in people.
Pep-Pedia bibliography · Checked 2026-10-12
3Adipotide in obese Old World monkeysAbstract checked
AI-PREPARED SUMMARY
Primate experiment found weight and fat loss with reversible renal proximal-tubule changes; no human efficacy conclusion.
Primate weight loss with renal effects
Obese monkeys lost weight and white adipose tissue; renal proximal-tubule function changed. The study does not establish human safety.
Additional research · Checked 2026-10-12
4Pep-Pedia: Adipotide — community referenceCommunity source checked
AI-PREPARED SUMMARY
Accessed October 12, 2026. Secondary descriptions and bibliography; community schedules are unvalidated reports, not recommendations.
5Human adipose targeting – imaging validation (2018)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: A CKGGRAKDC imaging probe targeted white adipose tissue. Probe localization does not establish adipotide efficacy or safety.
Reported population / model
Human adipose tissue (ex vivo) & mouse in vivo
Reported study details
CKGGRAKDC MRI probe · Single/short courses · Specific WAT targeting demonstrated
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
6First-in-man phase 1 evaluation of Prohibitin-TP01 (NCT01262664)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The small dose-escalation program ended before producing an efficacy result; it does not demonstrate human weight-loss benefit.
Reported population / model
Adults with metastatic prostate cancer & obesity
Reported study details
Subcutaneous, dose‑escalation · Early termination; limited enrollment
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
7Reversal of obesity by targeted ablation of adipose tissuePep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Targeted vascular-cell death accompanied approximately 30% weight reduction in obese mice over four weeks.
Reported population / model
Mice (diet‑induced obesity)
Reported study details
CKGGRAKDC‑GG‑D(KLAKLAK)2 · Daily x 4 weeks · ~30% weight reduction; adipose vascular apoptosis; metabolic normalization
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
8Comment on: A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeysLinked reference · Not independently reviewed
REFERENCE NOTE
Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.
Pep-Pedia bibliography · Checked 2026-10-12
9Prohibitin/annexin 2 interaction regulates fatty acid transport in adipose tissueLinked reference · Not independently reviewed
REFERENCE NOTE
Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.
Pep-Pedia bibliography · Checked 2026-10-12
10Vascular-targeted nanotherapy for obesity: unexpected passive targeting mechanism to obese fat for the enhancement of active drug deliveryLinked reference · Not independently reviewed
REFERENCE NOTE
Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.
Pep-Pedia bibliography · Checked 2026-10-12
11Prohibitin ligands in cell death and survival: mode of action and therapeutic potentialLinked reference · Not independently reviewed
REFERENCE NOTE
Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.
Pep-Pedia bibliography · Checked 2026-10-12
12Adipose tissue-targeting nanomedicines for obesity pharmacotherapyLinked reference · Not independently reviewed
REFERENCE NOTE
Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.
Pep-Pedia bibliography · Checked 2026-10-12
13Pep-Pedia: Adipotide — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12